The Global Tribune

Alzheimer’s disease (AD) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight.

 Breaking News
  • No posts were found

Alzheimer’s disease (AD) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight.

March 16
11:58 2020
Alzheimer\'s disease (AD) Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight.

Alzheimer’s disease (AD) – Market Insights, Epidemiology, and Market Forecast-2030

Albany, US – DelveInsight has launched a new report on Alzheimer’s Disease Market Insights, Epidemiology and Market Forecast-2030

DelveInsight’s “Alzheimer’s disease (AD) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Alzheimer’s disease (AD), historical and forecasted epidemiology as well as the Alzheimer’s disease (AD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. It is estimated that 5 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060.
  2. Delveinsight estimates are based on the age of onset, AD is classified into early-onset AD (EOAD, onset 95% of affected (2014).
  3. AD affects an estimated 6.08 million people in the US, and approximately 200,000 people younger than 65 years with AD constitute the younger-onset US population with AD [2019].

 

Key benefits of the Report

1. Alzheimer’s disease market report covers a descriptive overview and comprehensive insight of the Alzheimer’s disease epidemiology and Alzheimer’s disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Alzheimer’s disease market report provides insights on the current and emerging therapies. 

3. Alzheimer’s disease market report offers a global historical and forecasted market covering drug outreach in 7 MM.

4. Alzheimer’s disease market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Alzheimer’s disease market.

Request for Sample Pages:  https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market

 “According to DelveInsight, more women than men have Alzheimer’s or other dementias.”

 

 

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. It is the most common cause of dementia (a continuous decline in thinking, behavioral and social skills that disrupts a person’s ability to function independently) accounting for ~60–80% of cases.

The exact cause of Alzheimer’s disease is unknown, although a number of things are thought to increase your risk of developing the condition. These include increasing age, a family history of the condition, previous severe head injuries, and lifestyle factors and conditions associated with cardiovascular disease. The most common early symptom of Alzheimer’s is difficulty in remembering newly learned information because Alzheimer’s changes typically begin in that part of the brain that affects learning.

In most people with Alzheimer’s, symptoms first appear in their mid-60s. On the basis of severity, Alzheimer’s disease can be classified as mild, moderate, and severe.

 “As per DelveInsight’s Analysis, Alzheimer’s is the sixth leading cause of death in the United States.”

Some of the key companies working on Alzheimer’s disease are:

  • Neurotrope bioscience
  • AgeneBio
  • Amarantus Bioscience
  • Alkahest
  • vTv Therapeutics
  • Axsome Therapeutics

And Many Others.

The launch of the emerging therapies is expected to significantly impact the Alzheimer’s disease treatment scenario in the upcoming years:-

 Drugs Covered:

  • Bryostatin-1
  • AGB101
  • Eltoprazine
  • AKST/GR F6019
  • Azeliragon (TTP488)
  • AXS-05

And Many Others.

Request a Free Sample Report @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market

 Table of Contents:

1. Key Insights

2. Executive Summary of Alzheimer’s disease (AD)

3. Competitive Intelligence Analysis for Alzheimer’s disease (AD)

4. Alzheimer’s disease (AD): Market Overview at a Glance

4.1. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2017

4.2. Alzheimer’s disease (AD) Total Market Share (%) Distribution in 2030

5. Alzheimer’s disease (AD): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Alzheimer’s disease (AD) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Alzheimer’s disease (AD) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Alzheimer’s disease (AD) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Alzheimer’s disease (AD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Alzheimer’s disease (AD) Treatment and Management

8.2. Alzheimer’s disease (AD) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Alzheimer’s disease (AD) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Alzheimer’s disease (AD): Seven Major Market Analysis

13.1. Key Findings

13.2. Alzheimer’s disease (AD) Market Size in 7MM

13.3. Alzheimer’s disease (AD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Alzheimer’s disease (AD) Total Market Size in the United States

15.1.2. Alzheimer’s disease (AD) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Alzheimer’s disease (AD) Total Market Size in Germany

15.3.2. Alzheimer’s disease (AD) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Alzheimer’s disease (AD) Total Market Size in France

15.4.2. Alzheimer’s disease (AD) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Alzheimer’s disease (AD) Total Market Size in Italy

15.5.2. Alzheimer’s disease (AD) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Alzheimer’s disease (AD) Total Market Size in Spain

15.6.2. Alzheimer’s disease (AD) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Alzheimer’s disease (AD) Total Market Size in the United Kingdom

15.7.2. Alzheimer’s disease (AD) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Alzheimer’s disease (AD) Total Market Size in Japan

15.8.3. Alzheimer’s disease (AD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Alzheimer’s disease (AD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

Related Reports:

Alzheimer’s Disease – Pipeline Insights, 2020

The Alzheimer’s disease report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alzheimer’s disease across the complete product development cycle, including all clinical and nonclinical stages.

Alzheimer’s Disease – Epidemiology Forecast to 2030

The Alzheimer’s disease epidemiology covered in the report provides historical as well as forecasted Alzheimer’s disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/